The Rapid Response Partnership Vehicle (RRPV) supports the Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure (MCM) product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats. It is an agile network of technologists, innovators, traditional contractors, large and small business, academia, and nonprofit research institutions that can respond rapidly and effectively to future pandemic or high consequence biological threats.

Medical Technology

Vaccines

Therapeutics

Our Collaborations